GB2323030A - Dietary supplements for immunocompromised patients - Google Patents
Dietary supplements for immunocompromised patients Download PDFInfo
- Publication number
- GB2323030A GB2323030A GB9705109A GB9705109A GB2323030A GB 2323030 A GB2323030 A GB 2323030A GB 9705109 A GB9705109 A GB 9705109A GB 9705109 A GB9705109 A GB 9705109A GB 2323030 A GB2323030 A GB 2323030A
- Authority
- GB
- United Kingdom
- Prior art keywords
- nutraceutical
- glutamine
- patients
- cancer
- immune compromised
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010061598 Immunodeficiency Diseases 0.000 title 1
- 235000015872 dietary supplement Nutrition 0.000 title 1
- 239000002417 nutraceutical Substances 0.000 claims abstract description 10
- 235000021436 nutraceutical agent Nutrition 0.000 claims abstract description 10
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 8
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 8
- 235000006708 antioxidants Nutrition 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 7
- 201000011510 cancer Diseases 0.000 claims abstract description 7
- 230000001010 compromised effect Effects 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 3
- 239000002773 nucleotide Substances 0.000 claims abstract description 3
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 3
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 3
- 235000020776 essential amino acid Nutrition 0.000 claims abstract 2
- 239000003797 essential amino acid Substances 0.000 claims abstract 2
- 208000031886 HIV Infections Diseases 0.000 claims description 4
- 230000001681 protective effect Effects 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract description 11
- 229940088594 vitamin Drugs 0.000 abstract description 7
- 229930003231 vitamin Natural products 0.000 abstract description 7
- 235000013343 vitamin Nutrition 0.000 abstract description 7
- 239000011782 vitamin Substances 0.000 abstract description 7
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 abstract description 5
- 238000002512 chemotherapy Methods 0.000 abstract description 5
- 238000001959 radiotherapy Methods 0.000 abstract description 5
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 abstract description 4
- 235000013734 beta-carotene Nutrition 0.000 abstract description 4
- 239000011648 beta-carotene Substances 0.000 abstract description 4
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 abstract description 4
- 229960002747 betacarotene Drugs 0.000 abstract description 4
- 239000011669 selenium Substances 0.000 abstract description 4
- 229910052711 selenium Inorganic materials 0.000 abstract description 4
- 229940091258 selenium supplement Drugs 0.000 abstract description 4
- 235000019165 vitamin E Nutrition 0.000 abstract description 4
- 239000011709 vitamin E Substances 0.000 abstract description 4
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 3
- 235000010374 vitamin B1 Nutrition 0.000 abstract description 3
- 239000011691 vitamin B1 Substances 0.000 abstract description 3
- 235000019164 vitamin B2 Nutrition 0.000 abstract description 3
- 239000011716 vitamin B2 Substances 0.000 abstract description 3
- 235000019158 vitamin B6 Nutrition 0.000 abstract description 3
- 239000011726 vitamin B6 Substances 0.000 abstract description 3
- 235000019154 vitamin C Nutrition 0.000 abstract description 3
- 239000011718 vitamin C Substances 0.000 abstract description 3
- 230000032823 cell division Effects 0.000 abstract description 2
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 abstract description 2
- 239000002243 precursor Substances 0.000 abstract description 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 2
- 229960001471 sodium selenite Drugs 0.000 abstract description 2
- 239000011781 sodium selenite Substances 0.000 abstract description 2
- 235000015921 sodium selenite Nutrition 0.000 abstract description 2
- 235000019163 vitamin B12 Nutrition 0.000 abstract description 2
- 239000011715 vitamin B12 Substances 0.000 abstract description 2
- 239000013589 supplement Substances 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 description 7
- 230000009469 supplementation Effects 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000011785 micronutrient Substances 0.000 description 2
- 235000013369 micronutrients Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000009894 physiological stress Effects 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 235000021270 cold food Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 150000002309 glutamines Chemical class 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
- -1 sodium selenite Chemical class 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000021269 warm food Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A nutraceutical designed for support of immune compromised patients which when administered to patients with immune compromised systems caused by diseases such as HIV, cancer, chemotherapy or radiotherapy will be utilised as a precursor in nucleotide synthesis. The essential amino acid in this nutraceutical will supplement the body's own production of glutamine which is required by the body during rapid cell division and during the production of antibodies. The nutraceutical also provides an adequate level of anti-oxidant vitamins which play a preventative role in the development of cancer by removing free radicals. The composition essentially comprises glutamine or a glutamine-rich peptide, beta-carotene, vitamins B1, B2, B6, B12, C and E and a source of selenium such as sodium selenite.
Description
A NUTRACEUTICAL SPECIFICALLY DESIGNED FOR SUPPORT OF IMMUNE
COMPROMISED PATIENTS.
Certain diseases or even medical treatments can lead to the immune response of the patient becoming impaired. Examples of the former and latter cases are respectively HIV infection and cancer chemotherapy/radiotherapy. This state is characterised by depression of the production of particular populatious of white blood cells and the individual becoming highly susceptible to opportunistic, often life threatening infections such as pneumonia.
Recent scientific research has highlighted the crucial role of the amino acid glutamine in the function of cells ofthe immune system, particularly lymphocytes, macrophages and natural killer cells(l). The glutamine is utilised as an energy source and as a precursor for bases in nucleotide synthesis during replication.(2)
Glutamine has been used in clinical nutrition with favourable results and minimal side effects at doses of up to 30 - 40g/day (3). It has been termed a "conditionally essential" amino acid (4) as during periods of physiological stress the large requirements of the immune system due to rapid cell division, protein synthesis and antibody production may exceed the capacity of the body to synthesise glutarnine from other dietary amino acids. Glutamine supplementation has in the past primarily been used to aid recovery in critically ill or post-operative patients and its potential in managing chronic disease states involving depression of the immune system such as AIDs or in the immune suppression caused by cancer chemotherapy/radiotherapy has yet to be realised
The important role of free radicals in disease is now becoming increasingly well understood (5).
Under normal conditions the levels of these extremely reactive and damaging species are controlled by antioxidant vitamins and enzyme systems naturally present in the body. However, under certain conditions of physiological stress or when the body is exposed to abnormal levels if ionising radiation or certain chemicals an excess of free radicals can exist leading to amongst other problems DNA damage and mutation (6). Thus, one problem associated with both cancer chemotherapy and radiotherapy is the development of secondary cancers (7).
Recent epidemiological evidence has suggested that increased intakes of the vitamin C, vitamin
E and pro-vitamin A (beta-carotene) play a preventative role in the development of cancer (8,9).
Further, in immune compromised patients levels of the key protective anti-oxidant enzyme superoxide dismutase are depressed ( 10) making them more susceptible to infection and probably indicating lowered anti-oxidant defence overall. Additional evidence supporting this view is provided by the result of a study of young children with HIV infection which revealed that plasma levels ofthe anti-ondant compound vitamin E and beta-carotene were significantly lower than in a healthy control group (11).
While not strictly an anti-oxidant vitamin, selenium supplementation at the level of 200 ,ug/day has been found to improve immune response in healthy volunteers (12) and some clinicians have proposed selenium supplementation as standard therapy for AIDs patients (13).
Thus supplementation with reasonable levels of anti-oxidant vitamins and micronutrients will be beneficial during chemo/radiotherapy and also in HIV infections.
In addition to the effects of the anti-oxidant vitamins discussed above there is increasing evidence that the B group vitamins may play a role in boosting natural defences against infection in irnrniinocompromised patients. In a study of several hundred AtDs patients supplementation with greater than the RDA of vitamin B1 and B2 and particularly vitamin B6 was associated with reduced mortality (14). it is thought that the B group vitamins may exert this effect as they are essential for DNA synthesis in the rapidly proliferating cell populations of the immune system.
The innovation step in the described invention is to extend the use of glutamine supplementation to the management of chronic disease states of the immune system and for the first time to combine this with other suitable micronutrients to produce the optimum boosting of the immune system. This combination is presented as a formulation that is easy for often nauseous patients to take to ensure good compliance.
According to a first aspect of the invention all the nutrients which are beneficial in boosting the immune system are provided from a single product.
According to a second aspect of this invention the nutrients described above are present in a form which enables it to be easily and conveniently taken by patients.
The formula has the versatility to be dispersed in flavoured or unflavoured drinks or alternatively to be mixed with warm or cold food.
The invention is further described by means of an example but not in any limatative sense;
Example
Glutamine (or an equivalent amount of glutamine in the form of a glutamine rich peptide specifically prepared for supplementation purposes) in the range of 20 - 50 g, preferably 30g
Vitamin B1
- in the range 100% to 1000% RDA (Recommended Daily Allowance),preferably 7mg
Vitamin B2 - in the range 100% to 1000% RDA, preferably 8mg
Vitamin B6 - in the range 100% to 1000% RDA, preferably lOmg Vitamin B12 - in the range 100% to 1000% RDA, preferably 5pg Pro-vitamin A (beta-carotene) - in the range lOmg to 100mg, preferably 20mg
Vitamin C - in the range 50% to 1000% RDA, preferably 200mg Vitamin E - in the range 50% to 1000% RDA, preferably 50mg
Selenium - in the form of a suitable salt, such as sodium selenite, equivalent to 100 9 of elemental selenium
The components are dry mixed using conventional pharmaceutical processing equipment such as high shear ribbon blenders. The bulk product is then filled into either tamper evident containers or single dose sachets or formulated into a liquid or gel formulation for oral use.
The example desonied is the recommended daily intake which may be taken in a single or divided dose.
References
1. LM Castell et al, Amino Acids, 7 231-243 (1994) 2. M S M Ardawi & E A Newsome, Essasys Biochem, 1-44 (1985) 3. T.R Ziegler et al J Parenteral & Enteral Nutrition, 14 137-147 (1990) 4. J.M.Lacey & D W Wilmore, Nutrition Revs 48 297-209 5. B Halliwell J Royal Soc. Med 82 747-752 (1989) 6. P.A. Cerutti The Lancet, 344, 862-863 (1994) 7. Lien and Ou J Clin Hosp. Pharm, 10 223 (1985) 8. B.N. Ames J.A.M.A., 273(14), 1077=1078 (1995) 9. A.T.Diplock Am J Clin Nutrition, 53, 1895-1935 (1991) 10. S Umeki et al, Clin.Chem ,33 (12) 2230-2233 (1987) 11. P Mastroiacovo et al lnt J Vit Nutr Res. 66, 141-145 (1996) 12. R Martin et al, Biol Trace Element Res 41, 103-114 (1994) 13. GNSchrauzer & JSacher, Chemico-Biol Interact, 91, 199-205 (1994) 14. AM Tang et al Am J Epidemiology, 143 (12), 1244 -1256 (1996)
Claims (6)
- CLAIMS 1. The manufacture of a nutraceutical specifically designed for support of immune compromised patients.
- 2. A nutraceutical providing energy for nucleotide synthesis
- 3. A nutraceutical which plays a role in preventing the devlopment of cancer
- 4. A nutraceutical with protective anti-oxidant propoerties
- 5. A nutraceutical containing a conditionally essential amino acid.
- 6. A nutraceutical to support immune compromised patients suffering from HIV infections
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9705109A GB2323030A (en) | 1997-03-12 | 1997-03-12 | Dietary supplements for immunocompromised patients |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9705109A GB2323030A (en) | 1997-03-12 | 1997-03-12 | Dietary supplements for immunocompromised patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB9705109D0 GB9705109D0 (en) | 1997-04-30 |
| GB2323030A true GB2323030A (en) | 1998-09-16 |
Family
ID=10809113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB9705109A Withdrawn GB2323030A (en) | 1997-03-12 | 1997-03-12 | Dietary supplements for immunocompromised patients |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2323030A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001078533A3 (en) * | 2000-04-18 | 2002-02-21 | Nestle Sa | Nutritional modules |
| WO2001093910A3 (en) * | 2000-06-05 | 2002-11-14 | Oekopharm Forschungs Und Entwi | Method for increasing the antioxidative potential of selenium-containing aqueous solutions |
| ES2196983A1 (en) * | 2000-12-13 | 2003-12-16 | Novartis Nutrition Ag | Infant formula with free amino acids and nucleotides |
| DE102008056044A1 (en) * | 2008-11-05 | 2010-05-12 | Unger, Detlef | Foot operated garbage bin cover opener comprises lever arm which is pressed upwards with operating lever on leverage over wheel axle center point which has fastening collar that is fastened to garbage bin cover arms |
| US7850996B2 (en) | 2001-12-04 | 2010-12-14 | Vis-Vitalis Lizenz-Und Handels Ag | Selenium-containing compositions and uses thereof |
| EP2344147A2 (en) * | 2008-09-19 | 2011-07-20 | Nestec S.A. | Nutritional support of the immune system during anti-cancer treatment |
| US10201566B2 (en) | 2011-02-16 | 2019-02-12 | Selo Medical Gmbh | Pharmaceutical preparation containing selenite or selenite-containing compounds for treating cervical dysplasia or carcinomas |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0087068A1 (en) * | 1982-02-12 | 1983-08-31 | Thomas Moses Dr. Beck | Nutritional supplement |
| WO1992009277A1 (en) * | 1990-12-03 | 1992-06-11 | Kabi Pharmacia Ab | Nutrient supply |
| EP0609701A1 (en) * | 1993-01-27 | 1994-08-10 | Ajinomoto Co., Inc. | L-cystein, L-cystine or L-glutamine as a supplementary therapeutic agent for the treatment of immunodeficiency syndrome |
| EP0705542A1 (en) * | 1994-09-21 | 1996-04-10 | Sandoz Nutrition Ltd. | Adolescent dietary composition |
-
1997
- 1997-03-12 GB GB9705109A patent/GB2323030A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0087068A1 (en) * | 1982-02-12 | 1983-08-31 | Thomas Moses Dr. Beck | Nutritional supplement |
| WO1992009277A1 (en) * | 1990-12-03 | 1992-06-11 | Kabi Pharmacia Ab | Nutrient supply |
| EP0609701A1 (en) * | 1993-01-27 | 1994-08-10 | Ajinomoto Co., Inc. | L-cystein, L-cystine or L-glutamine as a supplementary therapeutic agent for the treatment of immunodeficiency syndrome |
| EP0705542A1 (en) * | 1994-09-21 | 1996-04-10 | Sandoz Nutrition Ltd. | Adolescent dietary composition |
Non-Patent Citations (1)
| Title |
|---|
| Nature's Best Health for Life Catalogue 1996/7 pages 21,24 & 36-40 * |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7794744B2 (en) | 2000-04-18 | 2010-09-14 | Nestec S.A. | Nutritional modules |
| WO2001078533A3 (en) * | 2000-04-18 | 2002-02-21 | Nestle Sa | Nutritional modules |
| RU2277915C2 (en) * | 2000-06-05 | 2006-06-20 | Вис-Виталис Лиценц-Унд Хандельс Аг | Method of raising antioxidant potential of selenium-containing aqueous solutions |
| WO2001093910A3 (en) * | 2000-06-05 | 2002-11-14 | Oekopharm Forschungs Und Entwi | Method for increasing the antioxidative potential of selenium-containing aqueous solutions |
| ES2196983B1 (en) * | 2000-12-13 | 2005-03-01 | Novartis Nutrition Ag. | NUTRIENT POWDER FOR A CHILD FORMULA WITH FREE AND NUCLEOTID AMINO ACIDS. |
| ES2196983A1 (en) * | 2000-12-13 | 2003-12-16 | Novartis Nutrition Ag | Infant formula with free amino acids and nucleotides |
| US7850996B2 (en) | 2001-12-04 | 2010-12-14 | Vis-Vitalis Lizenz-Und Handels Ag | Selenium-containing compositions and uses thereof |
| US9801904B2 (en) | 2001-12-04 | 2017-10-31 | Selo Medical Gmbh | Selenium-containing compositions and uses thereof |
| US10231995B2 (en) | 2001-12-04 | 2019-03-19 | Selo Medical Gmbh | Selenium-containing compositions and uses thereof |
| US10231994B2 (en) | 2001-12-04 | 2019-03-19 | Selo Medical Gmbh | Selenium-containing compositions and uses thereof |
| EP2344147A2 (en) * | 2008-09-19 | 2011-07-20 | Nestec S.A. | Nutritional support of the immune system during anti-cancer treatment |
| DE102008056044A1 (en) * | 2008-11-05 | 2010-05-12 | Unger, Detlef | Foot operated garbage bin cover opener comprises lever arm which is pressed upwards with operating lever on leverage over wheel axle center point which has fastening collar that is fastened to garbage bin cover arms |
| US10201566B2 (en) | 2011-02-16 | 2019-02-12 | Selo Medical Gmbh | Pharmaceutical preparation containing selenite or selenite-containing compounds for treating cervical dysplasia or carcinomas |
| US10543228B2 (en) | 2011-02-16 | 2020-01-28 | Selo Medical Gmbh | Pharmaceutical preparation containing selenite or selenite-containing compounds for treating cervical dysplasia or carcinomas |
Also Published As
| Publication number | Publication date |
|---|---|
| GB9705109D0 (en) | 1997-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| USRE40849E1 (en) | Method of treatment of glutathione deficient mammals | |
| Girodon et al. | Effect of micronutrient supplementation on infection in institutionalized elderly subjects: a controlled trial | |
| Robert et al. | Micronutrient status in phenylketonuria | |
| US4751085A (en) | Human nutritional compositions containing taurine and vitamins and/or minerals | |
| US4629625A (en) | Human nutritional compositions containing taurine and vitamins and/or minerals | |
| US7786175B2 (en) | Anti-atherosclerosis composition containing carotenoids and method for inhibiting LDL oxidation | |
| MXPA05003088A (en) | Leucine-enriched nutritional compositions. | |
| RU2663017C2 (en) | Nutritional supplements for 50+ individuals for improving vitality, immunity, eye and bone health | |
| CN101212961A (en) | Hydroxymethylbutyrate composition and its application | |
| EP1797891A1 (en) | Total enteral nutritious composition | |
| WO2008046870A1 (en) | Long-term feed - cancer patient | |
| Liang et al. | Vitamins and immunomodulation in AIDS | |
| GB2323030A (en) | Dietary supplements for immunocompromised patients | |
| AU613076B2 (en) | Nutritional supplement | |
| US8535660B1 (en) | Nutritional supplements for pregnant women | |
| EP1633377B1 (en) | A method of treating or preventing chronic wounds and a complete nutritional composition comprising glycine and/or leucine for use therein | |
| MXPA06001706A (en) | Multivitamin syrup for children or young adults. | |
| CA2546472A1 (en) | Nutritional composition for wound healing | |
| CA2134707A1 (en) | Methods and compositions for retarding the aging process | |
| CN111972589A (en) | Dunaliella salina powder effervescent tablet for supplementing vitamin A | |
| de Pee et al. | Can increased vegetable consumption improve iron status? | |
| JPH0648954A (en) | High protein nutrient solution | |
| JP2000515874A (en) | Amino acid compositions and their use in treating tumor growth and metastasis | |
| AU2015101086A4 (en) | A dietary supplement composition as a prophylactic and treatment for skin diseases such as eczema and psoriasis and the like and method of treatment | |
| Week et al. | The relative utilization of alpha-tocopherol and alpha-tocopheryl acetate by humans |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |